Please try another search
For the six months ended 30 June 2018, Thevax Genetics Vaccine Co Ltd revenues was not reported. Net loss decreased 29% to NT$90M. Lower net loss reflects Research and Development Expenses decrease of 30% to NT$80.9M (expense), Administrative expenses decrease of 22% to NT$8.7M (expense), Interest Income increase of 8% to NT$255K (income). Basic Earnings per Share excluding Extraordinary Items increased from -NT$1.40 to -NT$0.97.
Period Ending: | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -89.6 | -109.47 | -126.49 | -188.05 |
Net Income | -90 | -107.88 | -126.3 | -180.88 |
Period Ending: | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Assets | 197.43 | 306.35 | 206.79 | 355.25 |
Total Liabilities | 42.02 | 61.82 | 31.52 | 47.74 |
Total Equity | 155.41 | 244.53 | 175.27 | 307.51 |
Period Ending: | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Period Length: | 6 Months | 12 Months | 6 Months | 12 Months |
Cash From Operating Activities | -72.95 | -213.54 | -118.08 | -305.02 |
Cash From Investing Activities | -0.33 | -10.76 | -5.75 | -11.7 |
Cash From Financing Activities | -13.16 | 230.06 | ||
Net Change in Cash | -86.28 | 3.4 | -126.09 | -317.36 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review